PDF(Pubmed)
Abstract：
Hematological malignancies (HMs) encompass a diverse group of blood neoplasms with significant morbidity and mortality. Immunotherapy has emerged as a validated and crucial treatment modality for patients with HMs. Despite notable advancements having been made in understanding and implementing immunotherapy for HMs over the past decade, several challenges persist. These challenges include immune-related adverse effects, the precise biodistribution and elimination of therapeutic antigens in vivo, immune tolerance of tumors, and immune evasion by tumor cells within the tumor microenvironment (TME). Nanotechnology, with its capacity to manipulate material properties at the nanometer scale, has the potential to tackle these obstacles and revolutionize treatment outcomes by improving various aspects such as drug targeting and stability. The convergence of nanotechnology and immunotherapy has given rise to nano-immunotherapy, a specialized branch of anti-tumor therapy. Nanotechnology has found applications in chimeric antigen receptor T cell (CAR-T) therapy, cancer vaccines, immune checkpoint inhibitors, and other immunotherapeutic strategies for HMs. In this review, we delineate recent developments and discuss current challenges in the field of nano-immunotherapy for HMs, offering novel insights into the potential of nanotechnology-based therapeutic approaches for these diseases.
摘要：
血液恶性肿瘤(HMs)包括具有显著发病率和死亡率的不同组的血液肿瘤。免疫疗法已成为HMs患者的一种有效和关键的治疗方式。尽管在过去十年中，在理解和实施HMs的免疫疗法方面取得了显著进步，几个挑战依然存在。这些挑战包括免疫相关的不良反应，治疗性抗原在体内的精确生物分布和消除，肿瘤的免疫耐受，和肿瘤细胞在肿瘤微环境（TME）内的免疫逃避。纳米技术，具有在纳米尺度上操纵材料特性的能力，有可能通过改善药物靶向和稳定性等各个方面来解决这些障碍并彻底改变治疗结果。纳米技术和免疫治疗的融合催生了纳米免疫治疗,抗肿瘤治疗的一个专门分支。纳米技术已经在嵌合抗原受体T细胞（CAR-T）治疗中找到了应用，癌症疫苗,免疫检查点抑制剂，以及其他针对HMs的免疫治疗策略。在这篇综述中，我们描述了最近的发展，并讨论了目前在纳米免疫治疗领域的挑战，为这些疾病的基于纳米技术的治疗方法的潜力提供了新的见解。
